Trial results

Tirzepatide in Idiopathic Intracranial Hypertension Trial

NCT07191873 on ClinicalTrials.gov · last registry update 2026-08-28

Recruiting now, toward 60 participants. Due to report August 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Change in intracranial pressure in Idiopathic Intracranial Hypertension (IIH) patients. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for hypertension — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.

Status

RECRUITING

Phase

P4

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Duke University

Sponsor type

Other

Enrollment

60

Started

2026-08-25

Primary completion

2027-08 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Change in intracranial pressure in Idiopathic Intracranial Hypertension (IIH) patients

Conditions studied

Idiopathic Intracranial Hypertension (IIH)

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.